Will cervical screening remain cost‐effective in women offered the next generation nonavalent HPV vaccine? Results for four developed countries

A next generation nonavalent human papillomavirus (HPV) vaccine (“HPV9 vaccine”) is being introduced in several countries. The aims of this study were to evaluate whether cervical screening will remain cost‐effective in cohorts offered nonavalent vaccines and if so, to characterize the optimal numbe...

Full description

Saved in:
Bibliographic Details
Published in:International journal of cancer 2016-12, Vol.139 (12), p.2771-2780
Main Authors: Simms, Kate T., Smith, Megan A., Lew, Jie‐Bin, Kitchener, Henry C., Castle, Philip E., Canfell, Karen
Format: Article
Language:English
Subjects:
Adult
Aged
Cancer
Cervical cancer
cervical screening
Cost-Benefit Analysis
Developed Countries
Female
HPV vaccine
Human papillomavirus
Humans
Mass Screening - methods
Medical research
Medical screening
Middle Aged
nonavalent HPV vaccine
Outcome Assessment (Health Care)
Papillomaviridae
Papillomavirus Infections - epidemiology
Papillomavirus Infections - prevention & control
Papillomavirus Vaccines - immunology
primary HPV screening
Quality-Adjusted Life Years
Uterine Cervical Neoplasms - epidemiology
Uterine Cervical Neoplasms - prevention & control
Vaccination
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!